Ask AI

Breast Cancers

Share

Program Content

Events

Activities

  • EMBER 3 PROs
    EMBER-3 Patient-Reported Outcomes: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After PD on Previous ET
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2025

    Expires: December 01, 2025

  • ASCENT 04 KEYNOTE D19
    ASCENT-04//KEYNOTE-D19: Phase III Trial of First-line Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–Positive Advanced TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • VERITAC 2
    VERITAC-2: Phase III Study of Vepdegestrant vs Fulvestrant in Previously Treated ER-Positive/HER2-Negative Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • OptiTROP Breast05
    OptiTROP-Breast05: Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) in the 1L Treatment of Unresectable Locally Advanced/Metastatic TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • SERENA 6
    SERENA-6: Phase III Trial of ctDNA-Guided Switch to Camizestrant + CDK4/6i vs Continued AI + CDK4/6i Following ESR1 Mutation Emergence in HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2025

    Expires: December 02, 2025

  • NATALEE Menopausal Analysis
    NATALEE: Outcomes by Menopausal Status and Age From a Phase III Trial of Adjuvant Ribociclib + NSAI vs NSAI Alone in Patients With HR+/HER2- EBC 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • ELEVATE
    ELEVATE: Preliminary Safety and Efficacy of Elacestrant in Combination With Everolimus or Ribociclib in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • INAVO120
    INAVO120: OS From Phase III Study of 1L Inavolisib/PBO + Palbociclib + Fulvestrant in PIK3CA-Mutated, HR+/HER2-, Endocrine-Resistant Advanced Breast Cancer 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • DESTINY Breast09
    DESTINY-Breast09: Phase III Trial of Trastuzumab Deruxtecan ± Pertuzumab vs THP as 1L Treatment of HER2+ Advanced/Metastatic Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2025

    Expires: December 03, 2025

  • OASIS-4
    OASIS-4: Phase III Trial of Elinzanetant for Vasomotor Symptoms Associated With Endocrine Therapy in Patients With or at Risk for HR+ Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2025

    Expires: December 05, 2025

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.